SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC secures Priority Review Voucher associated with Sezaby approval

03 Feb 2026 Evaluate

Sun Pharma Advanced Research Company (SPARC) has secured a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby from United States Food and Drug Administration (USFDA). A PRV is a tradable voucher granted by the USFDA to encourage the development of new treatments for rare pediatric diseases, that can be redeemed to receive a priority review for a subsequent, separate drug application. The company intends to utilize the voucher to further accelerate its pipeline.

Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.

Sun Pharma Adv. Res Share Price

140.05 0.25 (0.18%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 451.55
Indegene 544.50
CMS Info Systems 286.90
JITF Infralogistics 300.00
Sagility 41.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×